On June 19, 2018 the U.S. Patent and Trademark Office issued U.S. Patent No.10,000,772 (‘the ‘772 patent) to The Regents of the University of California, the University of Vienna, and Dr. Emmanuelle Charpentier (collectively, “UC”), together the co-owners of foundational intellectual property relating to CRISPR/Cas9 genome editing technology. The patent covers methods of using optimized guide RNA formats (including single guide and dual guide formats) in certain environments including eukaryotic cells (such as human, animal, and plant cells). The ‘772 patent covers the use of RNA formats that are widely used in the industry.
The ‘772 patent claims priority to a U.S. provisional application, filed by UC on May 25, 2012. This application broadly encompasses the CRISPR/Cas9 genome editing technology invented by Drs. Jennifer Doudna’s and Emmanuelle Charpentier’s research teams.